Advice
Following a full submission
darunavir (Prezista) co-administered with low dose ritonavir and in combination with other antiretroviral medicinal products is accepted within NHS Scotland for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral therapy (ART) naïve adults.
After 48 weeks the combination of darunavir and ritonavir was non-inferior to a standard boosted protease inhibitor regimen in ART naïve adults. The combined regimen was associated with lower incidences of diarrhoea and lipid adverse effects
Download detailed advice88KB (PDF)
Medicine details
- Medicine name:
- darunavir (Prezista)
- SMC ID:
- 566/09
- Indication:
- Human immunodeficiency virus (HIV 1) infection in antiretroviral therapy (ART) naïve adults.
- Pharmaceutical company
- Tibotec (Janssen-Cilag Ltd)
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2009